Ganiyu Olatunbosun ARINOLA, Fabian Victory EDEM, Temitope Oluwagbenga ALONGE

Levels of Plasma C-reactive protein, Albumin and Pre-Albumin in Nigerian COVID-19 Patients

Aim: COVID-19 is a new viral, rapidly infectious and inflammatory disease, with no treatment currently.However, no study reported combination of high sensitive C-reactive protein (a marker of inflammation), albumin and prealbumin (markers of nutritional status) in the prognosis of COVID-19 among Nigerian COVID-19 patients. We assessed plasma levels of hsCRP, albumin, prealbumin, hsCRPalbumin ratio and hsCRP-prealbumin ratio in newly admitted COVID-19 patients and COVID-19 patients at discharge. Material and Methods: Albumin, pre-albumin and C-RP levels were determined in the plasma of confirmed cases of COVID-19 recruited form one Infectious Diseases Center, Ibadan, Nigeria using ELISA. hsCRP-albumin ratio and hsCRP-prealbumin ratio were calculated. All these parameters were compared in both groups of patients and controls. Results: hsC-RP level was significantly higher in newly admitted COVID-19 patients compared with discharged COVID-19 patients or COVID-19 free control (p0.05).The mean values of plasma hsC-RP, albumin and prealbumin in most COVID-19 patients (89%, 100% and 91% respectively) were within normal reference ranges. hsC-RP were significantly increased in newly admitted COVID-19 patients who were females, above 40 years of age and stayed above 10 days of hospital admission (p

PDF

___

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern.Lancet 2020;395:470-3.
2. Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest 2020;50.
3. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020;63:457-60.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan. China: a descriptive study. Lancet 2020;395:507-13.
5. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-22.
6. General office of the national health commission of China Covid-19 diagnostic and therapeutic regimen (trial 7th, edition) J Cardiopulm Rehabil Prev 2020;39:103-7.
7. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Uirusu 2003;77: 8801-11.
8. Schneider WM, Chevillotte MD, Rice CM. Interferonstimulated genes: a complex web of host defenses. Annu Rev Immunol 2014; 32:513-45.
9. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Vir 2020.
10. Anderson R, Schmidt R. Clinical biomarkers in sepsis. Front Biosci (Elite Ed) 2010;2:504-20.
11. Chalmers S, Khawaja A, Wieruszewski PM, et al. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: the role of inflammatory biomarkers. World J Crit Care Med 2019;8:59-71.
12. Matsumoto H, Kasai T, Sato A, et al. Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. Heart Vessels 2019;34:1961-8.
13. Ho KM, Lee KY, Dobb GJ, Webb SA. C-reactive protein concentration as a predictor of in-hospital mortality after ICU discharge: A prospective cohort study. Intensiv. Care Med 2008;34:481-7.
14. Villacorta H, Masetto AC, Mesquita ET. C-reactive protein: An inflammatory marker with prognostic value in patients with decompensated heart failure. Arq.Bras.Cardiol 2007;88:585-9.
15. Pearson TA, Mensah GA, Alexander RW, et al. Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice.A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association.Circulation 2003;107:499-511
16. Chertow GMAK, Lew NL, Lazarus JM, Lowrie EG. Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int 2000;58(6):2512-7.
17. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am SocNephrol 2007;18:2583-91.
18. Rambod M, Kovesdy CP, Bross R, et al. Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. Am J ClinNutr 2008;88:1485-94.
19. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364-74.
20. Artero A, Zaragoza R, Camarena JJ, et al. Prognostic factors of mortality in patients with communityacquired bloodstream infection with severe sepsis and septic shock. J. Crit. Care 2010;25:276-81.
21. Druml W. Nutritional management of acute renal failure.Am J Kidney Dis 2001;37:89-94.
22. Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and metaanalysis. Int J Infect Dis 2020;96:13-5.
23. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
24. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. EurRespir J 2020; 55:2000547.
25. Adigun K, Arinola OG, VF Edem, OM Ige. Plasma levels of C-reactive protein and fibrinogen in pulmonary tuberculosis patients in Ibadan, Southwest, Nigeria. Afr J of Biomedical Research 2017;20:127-30.
26. HuangJ ,Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol 2020.
27. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020.
28. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical Significance. JPEN J Parenter Enteral Nutr 2019;43:181-93.
29. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020;395:1054-62.
30. Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int 2020;40:2095-103.
31. Rothschild MA, Oratz M, Schreiber SSJH. Serum albumin.Hepatology 1988;8: 385-401.
32. Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection. Clinicachimicaacta 2020;509:91- 4.
33. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75:1730-41.
34. Siatka C, Eveillard M, Nishimura J, et al. COVID-19 screening, prognosis and severity evaluation with biomarkers formanagement of patients. Article Horiba. 2020; 18: static.horiba.com/fileadmin/Horiba/ Products/...
35. Kudou K, Saeki H, Nakashima Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. J Gastroenterol Hepatol 2019;34:355-63.
36. Yang JR, Xu JY, Chen GC, et al. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study. Sci Rep 2019;9:8143.
37. Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels.J Am CollCardiol 2005;46:464-9.
38. Lakoski SG, Cushman M, Criqui M, et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 2006;152:593-8.
39. Cesari M, Kritchevsky SB, Baumgartner RN, et al. Sarcopenia, obesity and inflammation - Results from the TRAIN study. Am J ClinNutr 2005;82:428-34.